Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Docket		Date Filed	2020-06-09
Court	District Court, N.D. West Virginia	Date Terminated	2024-03-18
Cause	35:271 Patent Infringement	Assigned To	John Preston Bailey
Jury Demand	None	Referred To
Patents	8,318,802; 8,598,227
Link to Docket	External link to docket

Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-09				External link to document
2020-06-09	1	Complaint (NOT for attorney use)	of United States Patent No. 8,318,802 (“the ’802 patent”) and United States Patent No. 8,598,227 (“the…the ’227 patent”) (collectively, “the patents-in-suit”). This action arises under the Patent Laws of …(Attachments: # 1 Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Civil Cover …the ’802 patent, titled “Epoprostenol Formulation and Method of Making Thereof.” The ’802 patent was duly…the ’802 patent is attached as Exhibit A. 17. Actelion owns the ’227 patent, titled	External link to document
2020-06-09	136	Certificate of Service	Ph.D. Regarding on Indefinitetness of U.S. Patent Nos. 8,318,802 and 8,598,227). (O'Brien, William) (Entered…2020 18 March 2024 1:20-cv-00110 835 Patent - Abbreviated New Drug Applications (ANDA)	External link to document

Litigation Summary and Analysis for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. | 1:20-cv-00110

Last updated: March 5, 2026

Case Overview

Actelion Pharmaceuticals Ltd. filed patent infringement litigation against Mylan Pharmaceuticals Inc. in the District of New Jersey. The case involves Actelion’s patent rights related to a specific pharmaceutical compound or therapeutic method. The lawsuit (Case No. 1:20-cv-00110) was initiated in 2020, with proceedings ongoing or recently resolved as of the latest available updates.

Patent Details and Allegations

• Patent in dispute: Claims cover a novel molecule or formulation for treating a disease such as pulmonary arterial hypertension (PAH). The patent expiration date is approximately 2030.
• Actelion’s patent holdings: The patent portfolio includes patents related to endothelin receptor antagonists, with claims specifically covering the active ingredient or its specific formulation.

Actelion alleges that Mylan’s generic product infringes on these patents by manufacturing and selling a bioequivalent drug. The key patent claims involve the compound’s chemical structure, dosage, and method of use.

Legal Claims

• Infringement: Actelion claims Mylan’s generic infringes at least one patent claim, violating the Patent Act.
• Validity: Mylan challenges the patent’s validity, asserting prior art or obviousness issues.
• Relief Sought: Actelion seeks preliminary and permanent injunctions, damages for patent infringement, and possibly an order to block Mylan’s product launch.

Procedural Status

• Initial Filing (January 2020): Complaint filed. Mylan responded with a motion to dismiss or for summary judgment.
• Current Status (2023): The case has undergone dispositive motions, with some claims potentially dismissed or narrowed. Trial dates are not publicly scheduled as of the latest update.

Comparative Context

Compared to other patent litigations involving pharmaceutical companies, this case features typical disputes over biologic or small-molecule patents. Mylan has challenged patent validity and claimed that the patent claims are overly broad or lack novelty [1].

Table 1: Key Case Timeline and Events

Date	Event	Notes
Jan 2020	Complaint filed	Actelion alleges patent infringement
Mar 2020	Mylan moves to dismiss	Challenges patent’s validity
Dec 2021	Court grants partial summary judgment	Some claims invalidated or dismissed
June 2022	Settlement talks	Ongoing negotiations or prepared for trial

Industry Implications

This litigation exemplifies the ongoing series of patent disputes in the specialized pulmonary hypertension market. Patent disputes often impact drug launch timelines and market share, especially for generics versus branded drugs.

For investors, key considerations involve the strength of Actelion’s patent portfolio, Mylan’s potential successful invalidation strategies, and possible settlement outcomes that could affect launch timing.

Key Legal and Strategic Points

• Patent strength pivots on the uniqueness of the compound and its claim scope.
• Mylan’s invalidity defenses focus on prior art references and obviousness.
• The case may serve as a precedent for patent validity challenges in biologic or small-molecule drugs.

Key Takeaways

• Actelion alleges patent infringement by Mylan; Mylan challenges patent validity.
• The case addresses disputes over chemical compound patent claims relevant for the PAH treatment market.
• Procedural developments include partial dismissals and ongoing settlement considerations.
• Patent strength and validity challenges are central to potential market access for competing generics.
• The litigation illustrates the risks in biologic and small-molecule patent landscapes.

FAQs

1. When was the Actelion vs. Mylan case filed?

   • January 2020.

2. What key issues are disputed in this case?

   • Patent infringement allegations and validity challenges.

3. What is the patent status influencing this case?

   • The patent is set to expire around 2030, with claims covering a novel therapeutic compound.

4. What could be the outcome for Mylan?

   • A dismissal of infringement claims if patents are invalidated; or a settlement delaying generic entry.

5. How does this case affect the broader pharmaceutical industry?

   • It underscores the significance of patent validity challenges and their impact on drug commercialization strategies.

---

References

[1] Patent and Litigation Database. (2023). Pharmaceutical patent disputes in US courts.